Abstract library

43 results for "eukaryotic translation initiation".
#1320 Are eIFs Ingredients for Neuroendocrine Tumorigenesis?
Introduction: Neuroendocrine tumors (NETs) develop in almost any organ, therefore they are a very heterogeneous group of tumors. One of the major activities in every cell is the translation of mRNA to the corresponding protein, which plays an important role in cancer development. Crucial for this translation process are eukaryotic initiation factors (eIFs), which are themselves regulated by the mammalian target of Rapamycin (mTOR)-pathway. Mutation or deregulated expression of eIFs influences cell growth and proliferation, contributing to carcinogenesis. The incidence of NETs has increased fivefold over the last three decades.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: MSc. Nadine Gantenbein
Authors:
#726 Expression and Phosphorilation of mTOR Pathway and Antitumor Activity of mTOR Inhibitors in Neuroendocrine Tumors
Introduction: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the control of cancer cell metabolism, growth and proliferation. The mTOR pathway has attracted broad scientific and clinical interest, particularly in light of the ongoing clinical cancer trials with mTOR inhibitors in pts with neuroendocrine tumors (NETs). To identify the best candidates for treatment with mTOR inhibitors is challenging.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Concetta Sciammarella
Authors:
#1307 Expression of m-TOR Pathway Components in Gastric Neuroendocrine Neoplasms: A Pilot Study
Introduction: The mammalian target of rapamycin (mTOR) signaling pathway plays a key role in the regulation of cell proliferation, protein synthesis and neuroendocrine tumor growth.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Vera Delektorskaya
Authors:
#2226 Approaching NETs from Many Angles: A Medical Research Paradigm to Challenge New Zealand’s Research Traditions
Introduction: NETwork! is a multidisciplinary clinical and translational research program investigating NETs from several perspectives.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr Kate Parker
Authors:
#1003 Signalling Pathways in Bronchial Neuroendocrine Tumor Disease and Its Translation to Innovative Targets: The New Kid on the Block
Introduction: Bronchial neuroendocrine neoplasias comprise a wide spectrum of well-differentiated tumors (typical/atypical carcinoids) to undifferentiated carcinomas such as small (SCLC) and large cell (LC) neuroendocrine carcinomas with a fatal prognosis. Therapeutic options are unsatisfactory.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PD Dr. Patricia Grabowski
Authors:
#2100 OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Neuroendocrine Tumors Starting Lanreotide – Study Design
Introduction: Information provided to patients about burden and treatment of neuroendocrine tumors (NETs) may ease treatment adherence, outpatient monitoring, and improve quality of life (QoL), but can also cause anxiety. Data on how to individually adapt materials are insufficient and mainly derived from clinical trials.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Vincent Hautefeuille
Authors:
#483 Efficacy of Everolimus in Patients with Metastatic Insulinomas and Refractory Hypoglycemia: For the French Group of Endocrine Tumors (GTE-Renaten)
Introduction: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and Everolimus could be a new therapeutic option.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Miss Valérie Bernard
Authors:
#486 Benefit of Octreotide LAR in Patients with Neuroendocrine Midgut Tumors Who Previously Progressed on Placebo Therapy: Two Cases From the PROMID Study
Introduction: In the phase IIIb PROMID study, patients with advanced low-/intermediate-grade midgut neuroendocrine tumors (NET) received Octreotide LAR (O; 30 mg IM q28d) or placebo (P). Median time to tumor progression (TTP) was increased 8.3 mo in patients receiving O v. P (HR=0.34; 95% CI, 0.20-0.59; P<0.0001).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Anja Rinke
Authors:
#2027 Predictors of Antiproliferative Effect of Lanreotide Autogel (LA) as First-Line Therapy for Advanced Neuroendocrine Tumors (NETs)
Introduction: The antiproliferative properties of LA in GEP NETs were demonstrated in the recently published CLARINET study
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Faidon Laskaratos
Authors:
#2098 Systemic Anti-Cancer Therapies in Neuroendocrine Tumor Patients Impair Nutritional Status
Introduction: Malnutrition is a clinical relevant problem in NEN-patients (pts) independently influencing overall prognosis, particularly in pts undergoing chemotherapy (CTx). A poor nutritional status (NS) in pts of all WHO-grades was associated with a significantly shorter long-term outcome
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Sophie Pevny
Authors: